Literature DB >> 26209753

Lamotrigine induced DIHS/DRESS: Manifestations, treatment, and outcome in 57 patients.

Xiang-qing Wang1, Bin Lv2, Hong-fen Wang2, Xu Zhang2, Sheng-yuan Yu2, Xu-sheng Huang2, Jia-tang Zhang2, Cheng-lin Tian2, Sen-yang Lang3.   

Abstract

OBJECTIVE: To evaluate the clinical features, course, response to treatment, and outcome of lamotrigine induced drug-induced hypersensitivity syndrome (DIHS) or drug reaction with eosinophilia and systemic symptoms (DRESS).
METHODS: A comprehensive PubMed and Scopus search (covering the period from January 1999 through April 2014) of the English and non-English literature (with English abstract) was conducted to identify published reports of severe cutaneous adverse reactions (SCARs) associated with lamotrigine therapy.
RESULTS: This study population included 57 patients, of whom 38 (66.67%) were female and 19 (33.33%) were male. The latency period varied from 9 days to 120 days, with a mean of 27.58 ± 20.65 days. Multisystem involvement was present in 97.37% (37/38) patients. Systemic corticosteroids were administered to (61.29%) 19/31 patients. 35/38 (92.11%) patients recovered completely, one patient developed liver failure and needed liver transplant, one died from septic shock and one died from multiple organ failure.
CONCLUSIONS: We found a greater predominance of women with LTG-DIHS/DRESS, and 68.42% patients were >18 years of age. The presenting symptoms in most of patients were fever, skin rash, liver involvement, hypereosinophilia, and lymphadenopathy. Lamotrigine is associated to a rather high risk of severe cutaneous adverse reactions and to the risk of dying from such reactions, likes many other anticonvulsants. Early recognition and withdrawal of the suspected agent may avoid irreversible damage to the organs will be life saving.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anticonvulsant hypersensitivity syndrome; Antiepileptic drugs; Drug reaction with eosinophilia and systemic symptoms; Drug-induced hypersensitivity syndrome; Lamotrigine

Mesh:

Substances:

Year:  2015        PMID: 26209753     DOI: 10.1016/j.clineuro.2015.07.008

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  4 in total

1.  Spectrum of Cutaneous Adverse Reactions to Levetiracetam and Human Leukocyte Antigen Typing in North-Indian Patients.

Authors:  Bhargavi Ramanujam; Kavish Ihtisham; Gurvinder Kaur; Shivani Srivastava; Narinder Kumar Mehra; Neena Khanna; Mahip Singh; Manjari Tripathi
Journal:  J Epilepsy Res       Date:  2016-12-31

2.  Drug Reaction with Eosinophilia and Systemic Symptom Syndrome Induced by Lamotrigine.

Authors:  Song Hee Han; Min Seok Hur; Hae Jeong Youn; Nam Kyung Roh; Yang Won Lee; Yong Beom Choe; Kyu Joong Ahn
Journal:  Ann Dermatol       Date:  2017-03-24       Impact factor: 1.444

3.  Lamotrigine-induced DRESS with purpuric lesions in the oral mucosa.

Authors:  Burçin Cansu Bozca; Betül Unal; Erkan Alpsoy
Journal:  JAAD Case Rep       Date:  2020-04-23

Review 4.  Tolerated drugs in subjects with severe cutaneous adverse reactions (SCARs) induced by anticonvulsants and review of the literature.

Authors:  Fabrizio De Luca; Laura Michelina Losappio; Corrado Mirone; Jan Walter Schroeder; Antonella Citterio; Maria Gloria Aversano; Joseph Scibilia; Elide Anna Pastorello
Journal:  Clin Mol Allergy       Date:  2017-10-04
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.